<DOC>
	<DOC>NCT01473394</DOC>
	<brief_summary>The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder.</brief_summary>
	<brief_title>Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Men and women, 1870 years of age. Currently meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSMIVTR) criteria for Major Depressive Disorder. The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration. Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control. Patients with a history of meeting DSMIVTR criteria for any: manic, hypomanic or mixed episode, including bipolar disorder and substanceinduced manic, hypomanic, or mixed episode; any depressive episode with psychotic or catatonic features; panic disorder with or without agoraphobia; obsessivecompulsive disorder; schizophrenia, schizoaffective, or other psychotic disorder; bulimia or anorexia nervosa; presence of borderline personality disorder or antisocial personality disorder; mental retardation, dementia, amnesia, or other cognitive disorders; patients who are considered a suicide risk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Depression</keyword>
</DOC>